Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Country, Competition, Forecast & Opportunities, 2028

Europe soft tissue sarcoma market is expected to grow at a significant rate during the forecast period, 2024-2028. Rise in the incidence and prevalence of different types of cancers coupled with the increasing research & development (R&D) activities is anticipated to bolster the growth of the market. Rising number of people suffering from soft tissue sarcoma in the region is augmenting the growth of the market. The advent of advanced therapies such as targeted and biological are also a contributing factor. There is growing focus on personalized medicine along with the huge investment for anti-cancer treatment research, which is likely to discover the new paths for Europe soft tissue sarcoma treatment market in the coming future. Furthermore, there is an increase in number of clinical trials going on in the region which is facilitating the growth of the market. Rising ease in FDA approvals as well as the patent expiry of branded drugs are some of the factors fuelling the growth of the market.

Soft tissue sarcoma is a rare type of cancer that develops in soft tissues of a human body such as fat, muscle, nerves, fibrous tissues, or deep skin tissues. About 40 percent of the cases occur in the legs usually at or above the knee. Fifteen percent develop in the hands and arms, another 15 percent in the head and neck and remaining 30 percent in the shoulders, chest, abdomen, or hips. Moreover, it is not classified as tumour, but can be life-threatening if the cancer spreads in the human body.

Increasing Prevalence of Different Types of Cancers

Growing occurrences of various types of cancer which start in soft tissues such as tendons, fat, nerves, blood vessels, and others, are expected to propel the growth of the market. There is a rise in number of cases of sarcoma which is augmenting the growth of the market. According to the cancer research UK, there are about 4,300 new soft tissue sarcoma cases in England every year, which is around 12 every day. Elder population are more at risk as they can develop soft tissue sarcomas cancer. Around 40 in 100 soft tissue sarcomas (40%) are diagnosed in individual’s aged 65 or above.

Download Free Sample Report

Increasing Research & Development (R&D) Activities

There is rise in number of research activities on drugs and other therapies which is likely to bolster the growth of the market. Researchers are focusing on second-line therapies for the patients who relapse or are refractory as there is no approved therapies for the same. Heavy funding by the government as well as private sectors for the R&D purpose are facilitating the growth of the market.

Rise in Number of Clinical Trials

There are large number of clinical studies which are going on for the soft tissue sarcoma in the region, which is projected to bolster the growth of the market. There is total 578 clinical studies in Europe, out of which 242 studies are completed. For instance, in 2021, a clinical trial for the “NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms with Soft Tissue Sarcoma of the Extremity and Trunk Wall” was completed.

Market Segmentation

Europe soft tissue sarcoma market is segmented into treatment, disease type, end user, company, and country. Based on treatment, the market is divided into targeted therapy, chemotherapy, anti-angiogenesis drug, and radiation therapy. Based on disease type, the market is categorized into local sarcoma, regional sarcoma, and metastatic sarcoma. Based on end user, the market is bifurcated into hospitals & clinics, ambulatory surgical centers, and others. In terms of countries, the market is categorized into Germany, France, United Kingdom, Italy, Spain, Netherlands, Belgium, Sweden, Poland, and Greece.

Market Players

GlaxoSmithKline PLC, Eli Lilly Italia - S.p.A., Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG, Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd, and Integra LifeSciences Services France SASU, are some of the leading companies in the market.

Report Scope:

In this report, Europe soft tissue sarcoma market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Europe Soft Tissue Sarcoma Market, By Treatment:
• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drug
• Radiation Therapy
• Europe Soft Tissue Sarcoma Market, By Disease Type:
• Local Sarcoma
• Regional Sarcoma
• Metastatic Sarcoma
• Europe Soft Tissue Sarcoma Market, By End User:
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

·         Europe Soft Tissue Sarcoma Market, By Country:

• France
• Germany
• United Kingdom
• Italy
• Spain
• Belgium
• Netherlands
• Sweden
• Poland
• Greece

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Europe soft tissue sarcoma market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

• Profit margin analysis in case of direct and indirect sales channel.

It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]